Ruxolitinib Meets a Forgotten Malady
- 15 August 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 81 (2) , 355-357
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literatureExpert Opinion on Pharmacotherapy, 2024
- Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal InfectionsJournal of Fungi, 2024
- Partial human Janus kinase 1 deficiency predominantly impairs responses to interferon gamma and intracellular control of mycobacteriaFrontiers in Immunology, 2022
- Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance databaseScientific Reports, 2022
- Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosisHematology/Oncology and Stem Cell Therapy, 2021
- Delayed granulomatous eruption of the nose associated with ruxolitinibJAAD Case Reports, 2020
- Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance ReviewClinical Lymphoma Myeloma and Leukemia, 2020
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012